암 환자를 위한 가임력 보존(Oncofertility) 시장 : 전략적 인사이트 및 예측(2026-2031년)

The Fertility Preservation in Oncology (Oncofertility) Market is projected to grow at a CAGR of 10.3% over the forecast period, increasing from USD 1.90 billion in 2026 to USD 3.10 billion by 2031.

The global fertility preservation in oncology market, commonly referred to as the oncofertility market, is experiencing strong expansion as healthcare providers increasingly recognize the long-term reproductive implications associated with cancer treatment. Oncology therapies such as chemotherapy, radiation therapy, stem cell transplantation, immunotherapy, and targeted therapies may adversely affect fertility in both male and female patients. Fertility preservation procedures enable patients diagnosed with cancer to preserve reproductive potential before undergoing gonadotoxic treatments. The market includes sperm cryopreservation, oocyte freezing, embryo freezing, ovarian tissue cryopreservation, testicular tissue preservation, fertility counseling, and reproductive endocrinology services.

The rising global burden of cancer among younger populations remains one of the primary factors supporting market growth. Increasing incidences of breast cancer, leukemia, lymphoma, ovarian cancer, testicular cancer, cervical cancer, and pediatric cancers among adolescents and young adults are creating substantial demand for fertility preservation services. Improvements in cancer survival rates are also contributing to market expansion, as long-term survivorship and quality-of-life considerations become increasingly important within oncology care pathways.

Growing awareness regarding the impact of cancer therapies on fertility is significantly influencing market development. Healthcare providers, oncology organizations, and reproductive medicine specialists increasingly emphasize early fertility counseling and reproductive planning before initiation of cancer treatment. Clinical guidelines from oncology and reproductive health societies increasingly recommend fertility discussions as part of standard oncology care, supporting broader adoption of fertility preservation procedures.

Technological advancements in assisted reproductive technologies and cryopreservation techniques are further strengthening market growth. Improvements in vitrification, tissue freezing, embryo culture systems, ovarian stimulation protocols, and reproductive endocrinology procedures are enhancing preservation success rates and expanding treatment accessibility. Oocyte cryopreservation and ovarian tissue preservation technologies have demonstrated substantial clinical advancements, increasing confidence among healthcare providers and patients regarding long-term fertility outcomes.

The market is also benefiting from increasing integration of multidisciplinary oncology care models. Oncologists, reproductive endocrinologists, fertility specialists, surgeons, psychologists, and patient navigators increasingly collaborate to develop personalized fertility preservation strategies based on patient age, cancer type, treatment urgency, and reproductive goals. This integrated care approach improves patient counseling, treatment coordination, and long-term survivorship planning.

The expansion of precision medicine and personalized oncology is further influencing the market. As cancer therapies become increasingly individualized, fertility preservation planning is also becoming more patient-specific. Healthcare providers increasingly assess treatment-related fertility risks based on therapeutic regimens, genetic profiles, hormonal status, and reproductive health history. Personalized fertility counseling is improving treatment decision-making and patient engagement throughout oncology care journeys.

Digital healthcare technologies and telemedicine platforms are also supporting market expansion. Virtual fertility counseling services, remote patient education platforms, electronic medical records integration, and digital reproductive health management tools are improving accessibility to fertility preservation services. Telehealth platforms are particularly important for patients in underserved or geographically remote regions who may otherwise face barriers to specialist fertility care.

The market is witnessing growing investment from fertility clinics, hospitals, academic institutions, and reproductive health organizations. Research initiatives focused on fertility restoration, ovarian tissue transplantation, in vitro gametogenesis, stem-cell-based reproductive technologies, and hormone preservation are expanding scientific understanding and therapeutic capabilities within the field of oncofertility.

North America currently dominates the fertility preservation in oncology market due to advanced healthcare infrastructure, widespread awareness regarding reproductive health, strong oncology survivorship programs, and broad adoption of assisted reproductive technologies. Europe also represents a major market supported by increasing fertility awareness initiatives, favorable healthcare systems, and expanding reproductive medicine infrastructure. Asia Pacific is expected to witness rapid growth due to improving healthcare access, rising cancer incidence, increasing fertility awareness, and growing investment in reproductive medicine technologies across countries such as China, Japan, India, and South Korea.

Despite strong growth prospects, the market faces challenges related to high procedure costs, limited insurance coverage, ethical considerations, lack of awareness in developing regions, and time-sensitive treatment coordination. However, ongoing advancements in reproductive medicine, cryopreservation technologies, personalized healthcare, and survivorship-focused oncology care are expected to create substantial long-term growth opportunities for the fertility preservation in oncology market.

Market Drivers

Rising Cancer Incidence Among Reproductive-Age Populations

The increasing prevalence of cancer among adolescents, young adults, and reproductive-age individuals is one of the major drivers supporting the oncofertility market. Breast cancer, lymphoma, leukemia, and testicular cancer cases among younger populations continue to rise globally.

Cancer patients increasingly seek fertility preservation options before initiating gonadotoxic treatment regimens.

Improving Cancer Survival Rates

Advancements in oncology treatment have significantly improved survival outcomes for cancer patients. As survivorship rates increase, long-term quality-of-life considerations such as reproductive health and family planning are becoming increasingly important.

Healthcare providers are increasingly integrating fertility preservation counseling into comprehensive cancer care programs.

Technological Advancements in Cryopreservation and Reproductive Medicine

Continuous innovation in assisted reproductive technologies, cryopreservation systems, vitrification methods, and tissue preservation techniques is positively influencing the market. Modern fertility preservation technologies improve reproductive success rates and expand treatment options for oncology patients.

Advancements in ovarian tissue cryopreservation and oocyte freezing are particularly supporting market growth.

Increasing Awareness and Clinical Guidelines

Growing awareness regarding treatment-related infertility risks is accelerating adoption of fertility preservation services. Oncology societies and reproductive medicine organizations increasingly recommend fertility counseling before cancer treatment initiation.

Educational initiatives and patient advocacy programs are improving awareness among patients and healthcare professionals.

Expansion of Telemedicine and Digital Healthcare

Telehealth platforms and digital healthcare technologies are improving access to fertility counseling and reproductive medicine services. Virtual consultations and remote patient engagement systems support faster treatment coordination and broader accessibility.

Digital healthcare integration is particularly beneficial for patients in underserved healthcare environments.

Market Restraints

High Cost of Fertility Preservation Procedures

One of the major restraints affecting the fertility preservation in oncology market is the high cost associated with assisted reproductive procedures and long-term tissue storage. Cryopreservation, hormonal stimulation, laboratory procedures, and storage services may create financial burdens for patients.

Limited insurance reimbursement may further restrict treatment accessibility.

Time Constraints Before Cancer Treatment

Cancer patients often require urgent treatment initiation, which may limit the time available for fertility preservation procedures. Delays associated with ovarian stimulation and reproductive planning may create clinical challenges in aggressive cancer cases.

Healthcare providers continue to develop rapid-start fertility preservation protocols to address these limitations.

Limited Awareness in Developing Regions

Awareness regarding fertility preservation and reproductive survivorship remains limited in several low-income and developing healthcare markets. Lack of specialized reproductive medicine infrastructure and trained fertility specialists may affect service availability.

Healthcare disparities continue to influence market penetration across geographic regions.

Ethical and Regulatory Challenges

Certain fertility preservation procedures involving embryos, reproductive tissues, and pediatric patients may face ethical, legal, and regulatory complexities. Variability in national reproductive healthcare regulations may affect procedural accessibility and clinical adoption.

Healthcare organizations continue to establish ethical guidelines and standardized counseling frameworks.

Technology and Segment Insights

The fertility preservation in oncology market is segmented by procedure type, gender, cancer type, end-user, and geography. By procedure type, the market includes sperm cryopreservation, oocyte cryopreservation, embryo freezing, ovarian tissue cryopreservation, testicular tissue preservation, and ovarian suppression therapies. Sperm cryopreservation currently accounts for a substantial market share due to established clinical adoption, procedural simplicity, and widespread accessibility.

Oocyte cryopreservation and ovarian tissue preservation are witnessing rapid growth because of increasing awareness among female oncology patients and continuous technological advancements in reproductive medicine.

Based on gender, the market includes male fertility preservation and female fertility preservation. Female fertility preservation is emerging as a rapidly growing segment due to increasing breast cancer prevalence among younger women and broader adoption of reproductive endocrinology services.

By cancer type, the market includes breast cancer, hematologic malignancies, gynecological cancers, testicular cancer, pediatric cancers, and others. Breast cancer currently represents a major segment because of rising incidence rates among reproductive-age women and increasing survivorship awareness.

Hematologic malignancies such as leukemia and lymphoma also contribute significantly to market growth because of intensive chemotherapy regimens associated with fertility risks.

Based on end-user, the market includes hospitals, fertility clinics, academic and research institutes, and specialty oncology centers. Fertility clinics currently account for a substantial market share due to specialized reproductive medicine expertise and cryopreservation infrastructure.

Hospitals and oncology centers are increasingly integrating fertility preservation programs into multidisciplinary cancer care pathways.

Regionally, North America dominates the market due to advanced reproductive medicine infrastructure, widespread oncology survivorship programs, and high healthcare expenditure. Europe continues to witness significant growth supported by favorable healthcare policies and increasing fertility awareness initiatives. Asia Pacific is expected to experience rapid expansion due to improving healthcare access, growing fertility awareness, and rising oncology treatment volumes.

Competitive and Strategic Outlook

The fertility preservation in oncology market is highly competitive and characterized by the presence of fertility clinics, reproductive medicine providers, cryopreservation technology companies, and healthcare organizations. Key market participants include CooperSurgical, Inc., Vitrolife AB, FUJIFILM Irvine Scientific, Cryoport Systems, Inc., Genea Biomedx, Hamilton Thorne Ltd., Merck KGaA, Progyny, Inc., Monash IVF Group, and The Prelude Network.

Leading companies are increasingly focusing on advanced cryopreservation systems, reproductive diagnostics, telehealth integration, and patient-centered fertility care solutions to strengthen market positioning. Investments in vitrification technologies, laboratory automation, and fertility preservation research are accelerating across the industry.

Vitrolife and CooperSurgical continue to maintain strong market positions through comprehensive reproductive technology portfolios and fertility laboratory solutions. Cryoport Systems is increasingly expanding specialized cryogenic logistics and reproductive tissue transportation services.

Fertility clinics and oncology centers are also forming strategic collaborations to improve multidisciplinary patient care and streamline fertility preservation referrals. Partnerships between reproductive medicine providers, hospitals, and oncology networks are accelerating integration of fertility counseling into oncology treatment pathways.

The market is witnessing increasing focus on personalized reproductive medicine, pediatric fertility preservation, digital fertility platforms, and long-term survivorship care integration. Companies capable of improving accessibility, affordability, and treatment success rates are expected to strengthen long-term market competitiveness.

Conclusion

The global fertility preservation in oncology market is expected to witness strong growth due to rising cancer prevalence among younger populations, improving cancer survival rates, and increasing awareness regarding reproductive health preservation during oncology treatment.

Fertility preservation is becoming an increasingly important component of comprehensive oncology care by supporting survivorship planning, quality-of-life improvement, and long-term reproductive health management. Growing investment in assisted reproductive technologies, cryopreservation systems, and multidisciplinary oncology care is further strengthening market expansion.

Technological advancements in vitrification, tissue preservation, reproductive endocrinology, and digital healthcare integration are significantly improving treatment accessibility and clinical outcomes. However, challenges related to high procedural costs, limited awareness, ethical considerations, and treatment timing constraints continue to affect broader market adoption.

Despite these restraints, ongoing innovation in reproductive medicine, survivorship-focused oncology care, and personalized healthcare is expected to create substantial long-term growth opportunities for the fertility preservation in oncology market.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Overview
• 1.2 Key Findings
• 1.3 Market Attractiveness Analysis
• 1.4 Strategic Insights for Stakeholders

2. Disease & Epidemiology Analysis

• 2.1 Overview of Oncofertility
• 2.2 Impact of Cancer Therapies on Fertility
• 2.3 Global Cancer Incidence in Reproductive-Age Population
  • 2.3.1 Female Cancer Patients (Breast, Ovarian, Hematologic, Others)
  • 2.3.2 Male Cancer Patients (Testicular, Prostate, Hematologic, Others)
• 2.4 Fertility Risk Stratification by Treatment Type
  • 2.4.1 Chemotherapy-Induced Gonadotoxicity
  • 2.4.2 Radiation-Induced Fertility Impairment
  • 2.4.3 Surgical Impact on Reproductive Organs
• 2.5 Eligible Patient Population for Fertility Preservation
• 2.6 Utilization Rates of Fertility Preservation Techniques
• 2.7 Unmet Needs and Barriers to Adoption

3. Market Dynamics

• 3.1 Market Drivers
  • 3.1.1 Rising Cancer Incidence in Young Population
  • 3.1.2 Increasing Awareness of Fertility Preservation
  • 3.1.3 Advancements in Cryopreservation Technologies
  • 3.1.4 Favorable Clinical Guidelines (ASCO, ESHRE)
• 3.2 Market Restraints
  • 3.2.1 High Cost of Procedures
  • 3.2.2 Limited Access in Emerging Markets
  • 3.2.3 Ethical and Social Concerns
• 3.3 Market Opportunities
  • 3.3.1 Expansion of Fertility Clinics
  • 3.3.2 Integration of AI in IVF and Cryopreservation
  • 3.3.3 Government and NGO Initiatives
• 3.4 Market Challenges
  • 3.4.1 Lack of Standardized Protocols
  • 3.4.2 Variability in Reimbursement

4. Commercial & Market Access

• 4.1 Pricing Analysis of Fertility Preservation Procedures
• 4.2 Reimbursement Landscape
  • 4.2.1 Public vs Private Coverage
  • 4.2.2 Insurance Penetration by Region
• 4.3 Patient Access Programs
• 4.4 Clinical Guidelines and Adoption Trends
• 4.5 Referral Pathways (Oncology to Fertility Clinics)

5. Innovation & Pipeline Landscape

• 5.1 Overview of Emerging Technologies
• 5.2 Pipeline Fertility Preservation Approaches
  • 5.2.1 Ovarian Tissue Cryopreservation Enhancements
  • 5.2.2 Testicular Tissue Cryopreservation Research
  • 5.2.3 In Vitro Gametogenesis (Preclinical/Clinical Research)
• 5.3 Pipeline Classification by Phase
  • 5.3.1 Phase I
  • 5.3.2 Phase II
  • 5.3.3 Phase III
• 5.4 Mechanism of Action and Modality
• 5.5 Strategic Collaborations and Research Initiatives

6. Treatment Landscape

• 6.1 Standard Fertility Preservation Methods
  • 6.1.1 Oocyte Cryopreservation
  • 6.1.2 Embryo Cryopreservation
  • 6.1.3 Sperm Cryopreservation
  • 6.1.4 Ovarian Tissue Cryopreservation
  • 6.1.5 Testicular Tissue Cryopreservation
• 6.2 Adjunctive Therapies
  • 6.2.1 Gonadotropin-Releasing Hormone (GnRH) Agonists
• 6.3 Clinical Guidelines
  • 6.3.1 ASCO Recommendations
  • 6.3.2 ESHRE Guidelines
• 6.4 Treatment Algorithm by Patient Type

7. Market Size & Forecast

• 7.1 Market Definition and Scope
• 7.2 Historical Market Size (2021-2024)
• 7.3 Current Market Size (2025)
• 7.4 Forecast (2026-2031)
• 7.5 CAGR Analysis
• 7.6 Market Share by Key Segments

8. Market Segmentation

• 8.1 By Procedure Type
  • 8.1.1 Oocyte Cryopreservation
  • 8.1.2 Embryo Cryopreservation
  • 8.1.3 Sperm Cryopreservation
  • 8.1.4 Ovarian Tissue Cryopreservation
  • 8.1.5 Testicular Tissue Cryopreservation
• 8.2 By Indication
  • 8.2.1 Breast Cancer
  • 8.2.2 Hematologic Cancers
  • 8.2.3 Gynecological Cancers
  • 8.2.4 Testicular Cancer
  • 8.2.5 Other Cancers
• 8.3 By Therapy Type
  • 8.3.1 Hormonal Therapy
  • 8.3.2 Cryopreservation Media & Devices
• 8.4 By End User
  • 8.4.1 Fertility Clinics
  • 8.4.2 Hospitals
  • 8.4.3 Research Institutes
• 8.5 By Distribution Channel
  • 8.5.1 Direct Sales
  • 8.5.2 Distributors

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Market Size & Growth
  • 9.1.2 Demand Drivers
  • 9.1.3 Regulatory Overview
  • 9.1.4 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size & Growth
  • 9.2.2 Demand Drivers
  • 9.2.3 Regulatory Overview
  • 9.2.4 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size & Growth
  • 9.3.2 Demand Drivers
  • 9.3.3 Regulatory Overview
  • 9.3.4 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size & Growth
  • 9.4.2 Demand Drivers
  • 9.4.3 Regulatory Overview
  • 9.4.4 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size & Growth
  • 9.5.2 Demand Drivers
  • 9.5.3 Regulatory Overview
  • 9.5.4 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Market Size
  • 10.1.2 Epidemiology
  • 10.1.3 Regulatory Framework (FDA)
  • 10.1.4 Reimbursement
  • 10.1.5 Key Companies/Products
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 United States (FDA Regulations for ART & Biologics)
• 11.2 Europe (EMA & Medical Device Regulation - MDR)
• 11.3 Japan (PMDA Framework)
• 11.4 India (CDSCO & ART Regulation Act)
• 11.5 China (NMPA Guidelines)
• 11.6 Ethical Guidelines and Consent Policies
• 11.7 International Guidelines (ASCO, ESHRE)

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Positioning
• 12.3 Strategic Initiatives
  • 12.3.1 Mergers & Acquisitions
  • 12.3.2 Partnerships & Collaborations
  • 12.3.3 Product Launches
• 12.4 SWOT Analysis

13. Company Profiles

• 13.1 Vitrolife AB
  • 13.1.1 Key Products: G-Series Culture Media, CryoTools
  • 13.1.2 Indications: IVF and Cryopreservation
  • 13.1.3 Pipeline/Innovations
• 13.2 CooperSurgical Inc.
  • 13.2.1 Key Products: Origio Cryopreservation Systems
  • 13.2.2 Indications: Assisted Reproductive Technology
  • 13.2.3 Pipeline/Innovations
• 13.3 Cook Medical
  • 13.3.1 Key Products: MINC Incubators, Cryopreservation Media
  • 13.2.2 Indications: Fertility Preservation Procedures
• 13.4 FUJIFILM Irvine Scientific
  • 13.4.1 Key Products: Vit Kit Freeze/Thaw Media
  • 13.4.2 Indications: Oocyte and Embryo Preservation
• 13.5 Kitazato Corporation
  • 13.5.1 Key Products: Cryotop Method Devices
  • 13.5.2 Indications: Vitrification
• 13.6 Merck KGaA (Merck Serono)
  • 13.6.1 Approved Drugs: Gonal-f (follitropin alfa)
  • 13.6.2 Indications: Ovarian Stimulation
• 13.7 Ferring Pharmaceuticals
  • 13.7.1 Approved Drugs: Menopur (menotropins)
  • 13.7.2 Indications: Fertility Treatment
• 13.8 Genea Biomedx
  • 13.8.1 Key Products: Gavi Automated Vitrification System
  • 13.8.2 Indications: Embryo/Oocyte Cryopreservation
• 13.9 Hamilton Thorne Ltd.
  • 13.9.1 Key Products: CASA Systems, Laser Systems
  • 13.9.2 Indications: Sperm Analysis and ART
• 13.10 Thermo Fisher Scientific
  • 13.10.1 Key Products: Cryo Media and Lab Solutions
  • 13.10.2 Indications: Cell and Tissue Preservation

14. Future Outlook

• 14.1 Emerging Trends
• 14.2 Technological Advancements
• 14.3 Market Expansion Opportunities
• 14.4 Strategic Recommendations

15. Methodology

• 15.1 Research Approach
• 15.2 Data Collection Sources
• 15.3 Market Modeling and Forecasting
• 15.4 Validation and Triangulation